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BACKGROUND: Peritoneal carcinomatosis (PC) from gastric cancer has long been
regarded a terminal disease with a short median survival. New locoregional
therapeutic approaches combining cytoreductive surgery with perioperative
intraperitoneal chemotherapy (PIC) have evolved and suggest improved survival.
MATERIALS AND METHODS: A retrospective multicentric study was performed
in French-speaking centers to evaluate the toxicity and the principal prognostic
factors in order to identify the best indications. All patients had cytoreductive
surgery and PIC: hyperthermic intraperitoneal chemotherapy (HIPEC) and/or early
postoperative intraperitoneal chemotherapy (EPIC).
RESULTS: The study included 159 patients from 15 institutions between February
1989 and August 2007. The median follow-up was 20.4 months. HIPEC was the PIC
used for 150 procedures. Postoperative mortality and grade 3-4 morbidity rates
were 6.5 and 27.8%, respectively. By multivariate analysis, the institution had a
significant influence on toxicity. The overall median survival was 9.2 months and 1-,
3-, and 5-year survival rates were 43, 18, and 13%, respectively. The only
independent prognostic indicator by multivariate analysis was the completeness of
cytoreductive surgery. For patients treated by complete cytoreductive surgery, the
median survival was 15 months with a 1-, 3-, and 5-year survival rate of 61, 30, and
23%, respectively.
CONCLUSIONS: The therapeutic approach combining cytoreductive surgery with
PIC for patients with gastric carcinomatosis may achieve long-term survival in a
selected group of patients (limited and resectable PC). The high mortality rate
underlines this necessarily strict selection that should be reserved to experienced
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